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Summary
Misregulated transcription is linked to many human
diseases, and thus artificial transcriptional activators
are highly desirable as mechanistic tools and as re-
placements for their malfunctioning natural counter-
parts. We previously reported two artificial transcrip-
tional activation domains obtained from synthetic
peptide libraries screened for binding to the yeast
transcription protein Med15(Gal11). Here we demon-
strate that the transcriptional potency of the Med15
ligands is increased through straightforward struc-
tural alterations. These artificial activation domains
upregulate transcription via specific Med15 binding
interactions and do not function in mammalian cells,
which lack Med15. This functional specificity stands
in contrast to most natural or artificial activation do-
mains that function across all eukaryotic cell types.
The results indicate that the screening strategy holds
excellent promise for identifying peptide and small
molecule transcriptional activators that function by
unique mechanisms with advantageous specificity
properties.
Introduction
Transcriptional activators play an essential role in gene
regulation by recruiting the RNA polymerase II holoen-
zyme to the genes with which they are associated (Fig-
ure 1) [1]. Many human diseases are characterized by
aberrant gene transcription patterns linked to malfunc-
tioning transcriptional regulators [2, 3]. For example, in
the case of medulloblastoma, one of the most malig-
nant pediatric cancers, the concentration of the tran-
scriptional repressor REST/NRSF is abnormally high,
resulting in the suppression of genes critical for proper
differentiation of neuronal cells [4, 5]; recent evidence
suggests that upregulating the transcription of REST-
regulated genes can mitigate the tumorigenic potential
of medulloblastoma cells [6, 7]. Thus, artificial tran-
scriptional activators composed of small molecules or
proteins have emerged as important tools to better
characterize the relationship between aberrant tran-
scription patterns and disease and in the longer term,
to define key characteristics of transcription-based
therapeutics [8–10].
Natural activators are exquisitely specific in their
function, upregulating cognate genes in particular cell
types to predetermined levels upon demand [1]. Part of*Correspondence: amapp@umich.eduthat specificity is derived from one of the two essential
components of an activator, a DNA binding domain
(DBD) that recognizes cognate DNA sequences (Figure
1B). The other key component is an activation domain
(AD) that interacts with a variety of proteins that consti-
tute the transcriptional machinery and dictates the level
of gene upregulation [1]. The AD-transcriptional ma-
chinery interactions are tightly regulated by signaling
pathways because natural ADs exhibit promiscuous
binding behavior [11] that leads to uncontrolled tran-
scriptional stimulation. An additional layer of functional
specificity is imposed by transcriptional regulatory net-
works that dictate when and where a given activator is
expressed [12, 13], leading to cell-type specific function.
The functional specificity profile of artificial transcrip-
tional activators is much less sophisticated, and the most
success has been attained in gene targeting specificity
[9, 10, 14]. For example, artificial activators that upreg-
ulate predetermined genes have been constructed by
the replacement of endogenous DBDs with novel pro-
tein DBDs [15] or with synthetic variants such as pep-
tide nucleic acids [16], triplex-forming oligonucleotides
[17, 18], and hairpin polyamides [19]. In addition, artifi-
cial activators that function only in the presence of a
small molecule have been developed and offer some
control over the timing of gene activation, thus serving
as a substitute for the signaling pathways that regulate
natural AD function [20, 21]. As in natural activators, the
AD of artificial activators contacts the transcriptional
machinery to upregulate transcription. However, it is typi-
cally difficult to predict the level of transcriptional stim-
ulation that will be elicited by a given artificial activator
due to many additional factors that impact AD function.
These factors include the DBD to which the AD is at-
tached, the position of the DNA binding site relative to
the gene, the concentration of the AD present at the
gene, and the affinity of the AD for the transcriptional
machinery [11, 18, 19, 22–27]. Finally, artificial activa-
tors that target particular cell types or organisms re-
main elusive. This lack of specificity can largely be at-
tributed to the activation domains employed in artificial
activator construction. These are typically ADs derived
from or closely related to natural activators that in the
context of an artificial activator operate outside of the
endogenous regulatory pathways [9, 15, 25, 28–30].
Thus, the ADs interact with a wide range of protein
targets and, as a result, function in all eukaryotic sys-
tems [16, 24].
We previously described a strategy for identifying ar-
tificial ADs that employs a screen for ligands of an indi-
vidual transcriptional machinery protein (Figure 2) [31].
The focal protein of that study was Med15(Gal11) [32],
a common target of natural ADs that resides in the me-
diator complex of the yeast transcriptional machinery
[33, 34]. Among the ligands identified from two syn-
thetic peptide combinatorial libraries were two 8 resi-
due peptides that function as activation domains when
attached to a DBD and have sequence compositions
distinct from any known ADs (Figure 2). In this article,
we show that the activity of ADs discovered via the
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karyotes
(A) Schematic of transcriptional activation.
(B) The architecture of a transcriptional acti-
vator.screen can be increased by simple modifications such t
fas altering the DNA binding domain to which the AD
is attached, consistent with the function of most ADs. w
bHowever, we also find that the ADs are functionally de-
pendent on the presence of a single protein, the original B
mtarget Med15. This functional specificity stands in con-
trast to typical natural or artificial ADs, and, as demon- d
tstrated with one of the Med15-dependent ADs, leads
to cell-type-specific transcriptional activation. Further, M
although the experiments described here were carried
out using peptide-based activators, the screening
Estrategy is readily extendable to small molecule combi-
Nnatorial libraries, leading in the future to new classes
aof small-molecule-based transcriptional activators [35,
d36] that function in a cell-type-specific or organism-
dspecific manner.
a
rResults and Discussion
s
cThe Med15 ligands were initially evaluated in several
Tfunctional contexts in order to increase transcriptional
tpotency and facilitate subsequent experiments testing
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Figure 2. Discovery of Artificial Transcriptional Activators through a
fScreening Strategy [31]
w
(A) Two libraries of synthetic peptides were screened for their abil-
bity to bind to the transcription factor Med15.
p(B) Two of the resulting ligands showed good activity as transcrip-
tional activation domains in Saccharomyces cerevisiae compared f
to a natural AD sequence, VP2, when they were attached to a pro- a
tein DNA binding domain (LexA). f
(C) A schematic of the integrated reporter gene used for the in vivo i
activation studies. As indicated, the two DNA binding sites for LexA
swere positioned 50 bp from the TATA box. The transcriptional activ-
mity of each LexA fusion protein was measured by assaying β-galac-
tosidase activity. qhe requirement for Med15. Among the factors that af-
ect the potency of ADs are the DNA binding domain to
hich the AD is attached and the position of the DNA
inding site relative to the gene being upregulated.
oth of these factors were first investigated using the
ore potent of the Med15 ligands, 28 (Figure 2). In ad-
ition, artificial transcriptional activators of greater po-
ency were constructed using dimers and trimers of the
ed15 ligands as the activation domains.
xchanging the DNA Binding Domain
atural transcriptional activators are modular proteins,
nd activation domains typically function indepen-
ently of the identity of the DNA binding domain. ADs
erived from the potent viral protein VP16, for example,
ctivate transcription efficiently when fused to a wide
ange of DBDs, including entirely nonnatural versions
uch as polyamides [22, 25] or triplex forming oligonu-
leotides [18], although the level of transcription varies.
he ability of natural ADs to interact with multiple pro-
ein targets may account for this functional flexibility.
lthough changing the DBD and hence presentation of
he AD might affect interactions with a subset of tran-
cription protein targets, it is unlikely to affect all. How-
ver, given that our ligands were identified based upon
heir ability to bind to a single transcription protein, we
nitially chose a DBD that most closely mimicked the
resentation of the ligands in the binding screen. Thus,
ecause the peptides were attached to solid support
ith the amino terminus free, the selected ligands were
used to the LexA DBD at the amino terminus of the
rotein (Figure 2).
To test if the Med15 ligands require a particular pre-
entation to function as ADs, we first investigated the
unction of 28 fused to a commonly used DBD derived
rom the S. cerevisiae protein Gal4, Gal4(1-147). The
irst 50 residues of Gal4 form a Cys6-Zn cluster that
inds to DNA and the subsequent 50 mediate dimeriza-
ion through helix-helix interactions that enhance se-
uence-specific DNA binding [37, 38]. The remaining 47
mino acid residues serve as a linker region of unde-
ined structure between the AD and the DBD. A plasmid
as constructed encoding ligand 28 fused to the car-
oxyl terminus of Gal4(1-147). Thus, ligand 28 is dis-
layed in the opposite orientation (carboxy terminus
ree) relative to the original LexA fusion. This plasmid
nd the original 28+LexA construct were each trans-
ormed into yeast strains containing two cognate bind-
ng sites for either LexA or Gal4 positioned 191 bp up-
tream of a lacZ reporter gene. Activation levels
ediated by each of the DBD+28 fusions were then
uantitated by measuring β-galactosidase activity [39].
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tor was more potent than the 28+LexA fusion protein,
with 14.5-fold activation compared to the DBD alone.
Thus, the Med15 ligand does not require a free amino
terminus to function as an activator despite the original
screening conditions. The change in orientation from
amino terminus to carboxy terminus is not the only
factor contributing to the increase in function. In prelim-
inary experiments, attachment of 28 to the carboxy ter-
minus of the DBD Gal4(1-100) produced an activator
approximately 4-fold less active than Gal4(1-147)+28.
Thus, the additional linker residues present in the
Gal4(1-147)+28 fusion protein likely play a role in the
activity increase, projecting the ligand from the DNA
more effectively and providing more favorable condi-
tions for the Med15 interaction. A similar reliance upon
linkers has been noted with natural transcriptional acti-
vation domains such as ATF14 and VP2, both acid-rich
ADs derived from the potent viral coactivator VP16 [22,
25], as well as nonnatural activation domains [24]. Fu-Figure 3. Increasing the Activity of the Med15 Ligands
The transcriptional potency of each artificial transcriptional activator was measured by quantitating β-galactosidase activity using standard
methods [39] and fold activation levels were obtained by dividing that activity by that obtained with DNA binding domain alone. Each activity
bar represents the average of at least 3 independent experiments with the indicated errors (SDOM). See Table 1 for yeast strain details.
(A) The activity of ligand 28 fused to different DNA binding domains. Note that the position of the DNA binding sites in this yeast strain is
different than in the strain in which the results shown in Figure 2 were obtained.
(B) Promoter position-dependence of ligand 28 fused either to LexA (left two bars) or Gal4(1-147) (right two bars).
(C) The activity of 28, 17, and 32 fused to Gal4(1-147).box. These latter results parallel the activity of the
Table 1. Yeast Strains Used in This Study
Strain Genotype Source
JPY9::pZZ41 Matα his3D200 leu2D1 trp1D63 ura3-52 lys2D385 gal4D11::pZZ41a [23]
JPY52::JP185 Matα his3D200 leu2D1 trp1D63 ura3-52 lys2D385 gal4D11 med15::LYS2, URA::pJP185b [23]
JPY52::JP188 Matα his3D200 leu2D1 trp1D63 ura3-52 lys2D385 gal4D11 med15:LYS2, URA::pJP188c [23]
ZL2 Matα his3D200 leu2D1 trp1D63 ura3-52 lys2D385 gal4D11 med15:TRP1, URA::pJP169d [34]
apZZ41 contains two LexA binding sites 50bp upstream of the TATA box.
bpJP185 contains two Gal4 binding sites 50bp upstream of the TATA box.
cpJP188 contains two Gal4 binding sites 191bp upstream of the TATA box.
dpJP169 contains two LexA binding sites 191bp upstream of the TATA box.ture studies of a wider range of DNA binding domains
and linkers of varying composition will be employed to
quantify this effect.
DNA Binding Site Location
The position of the DNA binding site relative to the tran-
scription start site can also affect how much an activa-
tor upregulates a gene [23, 40–42]. Gal4(1-147)+28 was
tested in yeast strains bearing 2 binding sites either 50
bp or 191 bp upstream of the TATA box, again using
quantitative β-galactosidase assays. As illustrated in
Figure 3B, the relationship between potency and bind-
ing site position varied with the DNA binding domain
employed. For 28+LexA, function was better at a bind-
ing site distance of 50 bp from the TATA box, with fold
activity dropping by half when moved to 191 bp. The
opposite trend was observed with Gal4(1-147) as the
DBD. In that case, lower levels of activation were ob-
tained when the binding sites were closer to the TATA
Chemistry & Biology
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The transcriptional activity of each construct was measured by quantitating β-galactosidase activity in the yeast strain JPY52::JP188 and is
reported as a ratio to the activity of Gal4(1-147)+28 or Gal4(1-147)+32 (defined as 1). The activity shown is the average of 3 separate
experiments with the indicated error (SDOM). See the Experimental Procedures section for additional details. Multimers containing 4 copies
of each peptide were also constructed; however, yeast bearing these plasmids grew poorly and Western blots of the extracts indicated that
the tetramer constructs were expressed at very low levels.
(A) The relative fold activation of multimers of 28 on Gal4(1-147).
(B) The relative fold activation of multimers of 32 on Gal4(1-147) DBD.
(C) The relative fold activation of mixed dimeric constructs.Med15 protein itself when it is employed as an artificial t
oactivator. The fusion protein Gal4(1-147)+Med15 is a
potent activator at the 191 bp distance; at 50 bp, how- o
Lever, activity drops by half [23]. The results obtained
with Gal4(1-147)+28 are suggestive of a mechanism by w
twhich 28 specifically recruits Med15 to DNA in an orien-
tation analogous to the positioning in the Gal4 d
d(1-147)+Med15 fusion protein.
a
fLigands 17 and 32
For ligand 28, the best activity was obtained when t
pGal4(1-147) was used as a DBD and the DNA binding
sites were positioned 191 bp upstream relative to the p
tTATA box. Two additional activating ligands were then
tested in this functional context (Figure 3C). One of t
tthese is ligand 17, shown in Figure 2. The second is
ligand 32 (sequence AYFEVPSE), the next most active t
eligand identified in the original screen that interacts
with Med15 with an affinity similar to 28 and 17 (KD 1.3 i
aM versus 4.8 and 2.2 M, respectively). In addition,
the binding site of ligand 28 is distinct from those of 32
and 17 ([31] and Figure S3). Although the sequence of A
O32 is different from the other two artificial ADs, it bears
the most resemblance to the largest class of natural g
mactivation domains, the so-called acid-rich ADs that
typically contain polar residues interspersed with hy- g
udrophobic amino acids [1]. An example of this class of
ADs is VP2, a positive control used in the original bind- c
iing screen and functional assays (Figure 2B). Plasmids
encoding either 17 or 32 attached to the carboxyl termi- t
4nus of the Gal4(1-147) DBD were prepared by standard
methods and then transformed into the yeast strains w
sused in earlier experiments. As shown in Figure 3C, thewo ligands showed quite different effects. In the case
f 17, only 2-fold activity relative to the DBD alone was
bserved, comparable to the results obtained with the
exA DBD (Figure 2B). Similar results were obtained
hen 17 was fused to Gal4(1-100); in addition, moving
he binding sites closer to the transcriptional start site
id not provide an increase in activity (see Figure S1 for
etails). In contrast, ligand 32 exhibited quite modest
ctivity when fused to the amino terminus of LexA (1.4-
old) but, as shown in Figure 3C, the activity increased
o 11.5-fold when it was attached to Gal4(1-147), com-
arable to the activity of 28. Overall, these experiments
rovided two artificial activators with improved func-
ional profiles, Gal4(1-147)+28 and Gal4(1-147)+32, and
hese two activators were used for all further investiga-
ions. The results further indicate that the transcrip-
ional activity of ligands obtained from future screening
xperiments (small molecules or peptides) can be read-
ly improved by straightforward optimization experiments,
nalogous to typical artificial activation domains.
ctivation Domain Multimers
ne of the principle mechanisms by which levels of
ene transcription can be increased is through aug-
enting the local concentration of ADs present at a
iven gene, although the origin of this effect is poorly
nderstood [43–46]. This can be accomplished by in-
reasing the number of activators bound to DNA, lead-
ng to transcriptional levels greater than the sum of
hose observed with the individual activators [44, 46,
7]. Alternatively, the AD itself can be oligomerized
ithin a single transcriptional activator to produce a
imilar effect [27, 47, 48]. In one example, an artificial
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(A) The fold activity of 28 and 32 in yeast
strains with Med15, Med15(186-619), or
with no Med15 present (Med15 delete). Each
activity value is the average of three indivi-
dual experiments with the indicated error
(SDOM) See the Experimental Procedures
section for additional information.
(B) Fold activation in human embryonic kid-
ney 293 cells. HEK293 cells were transiently
transfected with plasmids coding for each
construct and SEAP activity was measured
using standard methods [59]. See Experi-
mental Procedures for details.activator containing two copies of a well-studied AD
derived from VP16 upregulated transcription 5-fold
more effectively than an activator containing a single
copy of the AD [48]. From the standpoint of artificial
activator design, the latter approach is particularly
attractive because it requires a change only in the
structure of the artificial transcriptional activator rather
than alteration of the regulatory DNA sequences asso-
ciated with the targeted gene in order to produce
greater levels of transcription.
To test if the potency of artificial activators con-
structed with our Med15 ligands could be further in-
creased by oligomerization, plasmids encoding the
Gal(1-147) DBD fused to one, two, or three copies of
either peptide 28 (Figure 4A) or peptide 32 (Figure 4B)
were constructed such that each peptide sequence
was separated from the next by a flexible linker sequence
(see Experimental Procedures). In addition, constructs
containing a single copy of 28 and 32 separated by the
linker sequence were also prepared (Figure 4C). The re-
sulting plasmids were then transformed into the yeast
strain used for the experiments shown in Figure 3, and,
as before, the activity of each construct was measured
as a function of β-galactosidase activity. The results of
the experiments are displayed as activation relative to
the level obtained with an artificial activator containing
a single copy of the ligand (Figure 4). For all of the di-
meric constructs, an approximately linear increase in
function was observed upon expanding the number of
peptide modules from 1 to 2, indicating that this is an
effective strategy for tuning potency. Similarly, the tri-
mer of 28 was 3-fold more active than Gal4(1-147)+28.
Among all of the constructs, only the trimer of 32 (Fig-
ure 4B) showed activity beyond a simple additive
increase with greater than 95% confidence (more than
three times the level of 32 alone); however, this is still well
below the cooperative levels observed with multimers
of acid-rich ADs [48]. This was somewhat unexpected
because of the three Med15 ligands, 32 bears the
greatest sequence resemblance to natural ADs with a
balance of polar/acidic and hydrophobic amino acids.
Comparable results were obtained when the number of
DNA binding sites was increased (data not shown). As
illustrated more fully in the following section, the overall
lack of cooperative function observed in these experi-
ments may be indicative of a distinct mechanistic dif-ference between the artificial ADs isolated from our
binding screen and most natural ADs.
Specificity of Function
Natural activation domains typically interact with a
number of transcriptional machinery proteins. The well
characterized yeast transcriptional activator Gal4, for
example, has more than 10 identified target proteins,
although the physiological relevance of all the interac-
tions has yet to be established [11, 26, 49–54]. One
consequence is that deletion or mutation of a single
transcription protein target rarely leads to complete
loss of activator function [34, 53, 55]. Our activator pep-
tides were identified based upon their ability to interact
with a single transcriptional machinery protein, how-
ever, and perhaps the most compelling question sur-
rounding their function is if the protein target Med15 is
required for them to activate transcription. To evaluate
this possibility, β-galactosidase assays were carried
out in a yeast strain in which Med15 had been deleted
from the genome. This experiment is possible because
Med15 is not an essential protein, although yeast bear-
ing this alteration exhibit a slow growth phenotype [56].
As shown in Figure 5, we compared the function of
Gal4(1-147)+28 and Gal4(1-147)+32 in yeast strains
either bearing Med15 (dark bars) or bearing no Med15
(white bars) and noted a nearly complete loss of func-
tion. This was in contrast to the positive control, Gal4
(1-147)+ATF14, a sequence taken from the potent viral
coactivator VP16, that showed only a 2-fold decrease
in activation levels. Although ATF14 is known to interact
with Med15, it has several additional putative targets in
the transcriptional machinery, and thus its function is
attenuated rather than abrogated in the absence of
Med15 [57].
This point was further investigated by carrying out
the same set of experiments using a yeast strain in
which the central region of Med15 (residues 186–619)
had been deleted [58]. This mutation minimized the del-
eterious phenotype of the Med15 delete strain and ena-
bled us to test if the binding sites for ligands 28 and 32
were in this region because the original binding screen
was carried out with this fragment. Gratifyingly, nearly
identical results were obtained, with 28 and 32 showing
little or no activity in this strain while the fold activation
of ATF14 was similar to the strain with Med15 present
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318(light bars). Taken together, these data suggest that M
gboth 28 and 32 are dependent upon a binding interac-
tion with Med15 for transcriptional activation to occur. c
pOne interesting feature of acid-rich ADs such as Gal4
or VP16 is that they function in all eukaryotes tested, s
vfrom yeast through humans [60–62]. Despite differ-
ences in RNA polymerase II holoenzyme composition, i
cthere is evidently significant conservation across spe-
cies with regard to activator targets. It has been chal- o
tlenging, however, to identify metazoan homologs of
Med 15 [33]. Recently, compelling evidence for homol- s
bogy between the amino terminus of Med15 and the
mammalian protein ARC105 was reported; both pro- e
mteins contain a so-called GACKIX domain often found
in targets of activators [63]. The significance of this b
tsimilarity has yet to be determined, however, because
the amino terminus of Med15 can be removed and
overall function is maintained [34]. In addition, the two E
proteins have sequence similarities in the carboxy ter-
Gminal region, including a glutamine-rich stretch of
Ramino acids. However, the region of Med15 used in our
woriginal binding screen (residues 186–619) shares little
m
sequence similarity with ARC105 or any other identified m
metazoan protein, and we thus anticipated that activa- o
stors that function through interaction with this region
pwould not be able to function in mammalian cells. To
Ttest this idea, a plasmid encoding the most active of
othe peptides (28) was transiently transfected into hu-
(
man embryonic kidney cells (HEK293 cells) along with D
a reporter plasmid bearing five Gal4 binding sites within M
oan E1b promoter upstream of a SEAP reporter gene fol-
olowing standard protocols. As a positive control, we
calso examined the activity of a VP16-derived activation
gdomain fused to Gal4(1-147), known to function well in
s
this system. As indicated in Figure 5B, no activation
by ligand 28 was observed while the VP16-derived AD
Pfunctioned well in this context. This data reinforces the 1
earlier results indicating that 28 is dependent upon P
Med15 for function, and further, indicates that the li- a
Ggand screening strategy can be used to identify artifi-
Pcial ADs that are specific for a particular cell type, de-
(pending on the target protein. Given the emerging role
nof cell-type-specific transcription factors and factors
G
expressed only at certain points in development (for ex- 3
ample, see [64, 65]), ligands for those proteins will be A
Gparticularly valuable for functionally specific artificial
Gactivator construction.
A
sSignificance p
l
pThe results presented here indicate that artificial acti-
Lvation domains discovered through a binding screen
cdiffer from typical natural or artificial ADs in several
qkey respects. Similar to natural ADs, the potency of arti-
tficial activators constructed from the Med15 ligands p
can be readily increased by simply reiterating the AD F
(sequences within the construct. In contrast, a strong
psynergistic increase in transcriptional levels is not
Gobserved. This is most likely related to the functional
Tspecificity of the ADs, as subsequent experiments re-
3
vealed that for at least two of the artificial ADs, Med15 i
is required for transcription function. In the future, ar- L
ctificial transcriptional activators constructed with theed15-specific ligands used in combination with li-
ands targeting other individual transcriptional ma-
hinery proteins will thus be outstanding tools for
robing the mechanistic origins of transcriptional
ynergy. Further, since the screening strategy pro-
ides activation domains that function through bind-
ng interactions with individual transcriptional ma-
hinery proteins, targeting other cell-type-specific or
rganism-specific proteins provides a mechanism for
he creation of artificial activators whose functional
pecificity extends beyond that imposed by the DNA
inding domain. Finally, as the screening strategy is
qually applicable to combinatorial libraries of small
olecules, these results provide a framework for
uilding tunable, uniquely specific small molecule
ranscriptional regulators.
xperimental Procedures
eneral Methods
estriction enzymes, T4 polynucleotide kinase, and T4 DNA ligase
ere purchased from New England Biolabs and used as recom-
ended. Oligonucleotides were obtained from Invitrogen. The plas-
id YCplac111 and all of the yeast strains used to test the activity
f our activator constructs were generously provided by Dr. A. An-
ari (University of Wisconsin) [66]. The plasmids pGBKT7,
G5SEAP, pM, and pM3-VP16 were obtained from BD Biosciences.
he human embryonic kidney 293 cells used for testing the activity
f 28 were purchased from the American Type Culture Collection
ATCC) and maintained as recommended. The QuikChange Site-
irected Mutagenesis Kit used to generate the YCplac111
ed15(186-619) plasmid was purchased from Stratagene. All
ther chemicals and supplies were purchased from Fisher unless
therwise noted. All techniques used for yeast manipulations were
arried out in accordance with standard protocols [39]. All other
eneral molecular biology techniques were carried out as de-
cribed [67].
lasmid Construction
7+LexA, 28+LexA, and 32+LexA
lasmids encoding 17+LexA, 28+LexA, and 32+LexA were gener-
ted from pNLexA (Origene) as previously described [31].
al4(1-147)+17, Gal4(1-147)+28, and Gal4(1-147)+32
lasmids encoding Gal4(1-147)+17, Gal4(1-147)+28, and Gal4
1-147)+32 were generated from pGBKT7 by first annealing oligo-
ucleotides encoding each peptide ligand, (5#-AA TTC GGT TCT
GT GGT TCT GGT NNN NNN NNN NNN NNN NNN NNN NNN TAA-
# and 5#-TCGA NNN NNN NNN NNN NNN NNN NNN NNN ACC
GA ACC ACC AGA ACCG-3# or 5#-AA TTC TGT GGT TCT GAT
CT TTG GAT GAT TTT GAT TTG GAT ATG TTG TAA-3# and 5#-TC
A TTA CAA CAT ATC CAA ATC AAA ATC ATC CAA AGC ATC AGA
CC ACA G-3#) resulting in sticky ends corresponding to the re-
triction sites EcoRI/SalI. The duplex oligonucleotides were phos-
horylated with T4 polynucleotide kinase and ligated with T4 DNA
igase into pGBKT7 predigested with EcoRI/SalI. The resulting
lasmids were amplified in DH5α E. coli (Invitrogen), selected on
B-agar plates containing 50 g/ml kanamycin, and isolated from
ultures using a QIAprep Spin Miniprep Kit (Qiagen). The se-
uences of the isolated plasmids were verified by sequencing at
he University of Michigan Core Facility.
M+28
or use in the human cell experiments, a plasmid encoding Gal4
1-147)+28 was generated from pM by ligation of an oligonucleotide
air encoding peptide 28 (5#-AA TTC GGT TCT GGT GGT TCT GGT
CT CAT TAT TAT TAT CCA TCT GAA TAA-3# and 5#-TCGA TTA
TC AGA TGG ATA ATA ATA ATG AGC AGA ACC ACC AGA ACCG-
#) into pM that had been predigested with EcoRI/SalI. The result-
ng plasmid was amplified in DH5α E. coli (Invitrogen), selected on
B-agar plates containing 0.1 mg/ml ampicillin and isolated from
ultures using a QIAprep Spin Miniprep Kit (Qiagen). The sequence
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319of the isolated plasmids was verified by sequencing at the Univer-
sity of Michigan Core Facility.
Gal4(1-147)+28x2, Gal4(1-147)+32x2, Gal4(1-147)+28+32,
and Gal4(1-147)+32+28
To construct plasmids encoding the Gal4(1-147)+28x2, Gal4
(1-147)+32x2, Gal4(1-147)+28+32, and Gal4(1-147)+32+28 fusions,
two pairs of oligonucleotides coding for each of the peptides and
linkers were designed and separately annealed. The annealed oli-
gonucleotides for either peptide 28 or peptide 32 (5#-AATTT GGT
TCT GGT GGT TCT GGT NNN NNN NNN NNN NNN NNN NNN NNN
GGT ACC G-3# and 5#-GATCC GGTACC NNN NNN NNN NNN NNN
NNN NNN NNN ACC AGA ACC ACC AGA ACC A-3#) contained
sticky ends complementary to EcoRI/BamHI sites and an additional
KpnI site upstream of the BamHI sticky end. The second set of
annealed oligonucleotides for peptide 28 or peptide 32 (5#-GATCC
GGT TCT GGT GGT TCT GGT NNN NNN NNN NNN NNN NNN NNN
NNN TAA G-3# and 5#-TCGAC TTA NNN NNN NNN NNN NNN NNN
NNN NNN ACC AGA ACC ACC AGA ACCG-3#) contained sticky
ends complementary to BamHI/SalI sites. The two sets of annealed
oligonucleotides were 5# phosphorylated using T4 polynucleotide
kinase. Both pairs of annealed oligonucleotides were then ligated
simultaneously with T4 DNA ligase into EcoRI/SalI digested
pGBKT7. The resulting plasmids were amplified in SMART E. coli
cells (Gene Therapy Systems), selected on LB-agar plates contain-
ing 50 g/ml kanamycin, and isolated from cultures using a QIA-
prep Spin Miniprep Kit (Qiagen). The sequences of the isolated
plasmids were verified by sequencing at the University of Michigan
Core Facility.
Gal4(1-147)+28x3 and Gal4(1-147)+32x3
To construct plasmids encoding Gal4(1-147)+28x3 and Gal4
(1-147)+32x3, the respective Gal4(1-147) dimer construct, either
Gal4(1-147)+28x2 or Gal4(1-147)+32x2 was sequentially digested
with KpnI and BamHI. Oligonucleotides corresponding to 28 or 32
(5#-T GGT TCT GGT GGT TCT GGT NNN NNN NNN NNN NNN NNN
NNN NNN TTC G-3# and 5#-GATCC GAA NNN NNN NNN NNN NNN
NNN NNN NNN ACC AGA ACC ACC AGA ACC AGTAC-3#) were
annealed, resulting in sticky ends complementary to KpnI/BamHI
sites and forming an EcoRI site upstream of the BamHI site. These
annealed oligonucleotides were 5# phosphorylated using T4 poly-
nucleotide kinase and then ligated with T4 DNA ligase into KpnI/
BamHI digested Gal4(1-147)+28x2 or Gal4(1-147)+32x2, amplified
in SMART E. coli cells (Gene Therapy Systems), isolated from cul-
tures using a QIAprep Spin, Miniprep Kit (Qiagen), and sequenced
at the University of Michigan Core Facility.
Med15D(186-619)
The YCplac111+Med15(186-619) plasmid was generated from the
parent YCplac111 full-length Med15 plasmid using site-directed
mutagenesis. Briefly, two sets of oligonucleotides were designed
to insert XhoI restriction sites either after nucleotide 558 (last nu-
cleotide in codon for amino acid 186) or before nucleotide 1858
(first nucleotide in amino acid 620 of Med15). The first set, (5#-CAA
TTA CTG CAA AGA ATT CTC GAG CCT AAC ATT CCA CCC-3# and
5#-GGG TGG AAT GTT AGG CTC GAG AAT TCT TTG CAG TAA
TTG-3#) with homology to the region surrounding nucleotide 558,
was used to amplify the parent YCplac111 plasmid that encodes
full-length Med15. The methylated parent plasmid was then di-
gested with DpnI and the nicked mutagenized plasmid was ampli-
fied in SMART E. coli cells (Gene Therapy Systems), selected on
LB-agar plates containing 0.1 mg/ml ampicillin and isolated from
cultures using a QIAprep Spin Miniprep Kit (Qiagen). This modified
plasmid was then subjected to the same mutagenesis procedure
using the second set of oligonucleotides, (5#-GGG AAA GTA TGA
GAA TTC TCG AGC AAA TTT TAA GAA GAC-3# and 5#-GTC TTC
TTA AAA TTT GCT CGA GAA TTC TCA TAC TTT CCC-3#) designed
to insert an XhoI restriction site upstream of nucleotide 1858 of
Med15. After insertion of both of the XhoI restriction sites, the am-
plified plasmid was digested with XhoI then gel purified and the
resulting YCplac111+Med15(186-619) plasmid was religated with
T4 DNA ligase, amplified in SMART E. coli cells and selected on
LB-agar plates containing 0.1 mg/ml ampicillin. The new
YCplac111+Med15(186-619) plasmid was subsequently isolated
using a QIAprep Spin Miniprep Kit (Qiagen) and the sequence was
verified at the University of Michigan Core Facility.-Galactosidase Assays
The function of the ligand-DBD fusions were examined in yeast
by a quantitative liquid β-galactosidase assay in accordance with
established methods [39]. Briefly, the plasmids encoding the
ligand+DBD fusions and the DBD plasmid (negative control) were
transformed into yeast using the LiOAc method or by electropora-
tion, and transformed colonies were selected by growth on syn-
thetic complete (SC) media containing 2% raffinose and lacking the
appropriate amino acid(s) for selection. Freshly transformed colo-
nies were used to inoculate 5 ml cultures of SC media containing
2% raffinose and lacking the appropriate amino acids. The cultures
were incubated overnight at 30°C with agitation. Following incuba-
tion, these cultures were used to inoculate 5 ml cultures of SC
media containing 2% raffinose, 2% galactose and lacking the ap-
propriate amino acids that were subsequently incubated overnight
at 30°C with agitation to an OD660 of 0.6–0.9. The yeast cells were
harvested and resuspended in breaking buffer (100 mM Tris-HCl
(pH 8.0), 20% glycerol) containing the Complete Protease Inhibitors
cocktail (Roche). The cells were lysed by vortexing with glass
beads. A portion of the cell extract was used to measure β-galacto-
sidase activity via incubation with o-nitrophenyl-β-D-galactopy-
ranoside (1 mg/ml) in Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4,
10 mM KCl, 1 mM MgSO4•7H2O, and 50 mM 2-mercaptoethanol
[pH 7]). The reaction was stopped by adding 1 M Na2CO3 and the
OD420 was measured on a Varian Cary 300 UV-vis spectrometer.
The activity reported was normalized to the total protein concentra-
tion of the extract, measured using a Bradford assay kit (Bio-Rad)
with BSA as the standard. Western blot analysis was conducted on
each reaction to confirm appropriate expression of each of the
constructs.
Secreted Alkaline Phosphatase Assay
The function of Gal4(1-147)+28 was examined in human cells using
a quantitative secreted alkaline phosphatase (SEAP) assay in ac-
cordance with standard protocols [59]. For this purpose, 4 g of
plasmid encoding Gal4(1-147)+28, the Gal4(1-147) plasmid (pM,
negative control), or the Gal4(1-147)+ VP16(411-455) fusion (pM3-
VP16, positive control) were transiently transfected into an equal
number of human embryonic kidney 293 cells (ATCC) using the
PolyFect reagent (Qiagen) according to the manufacturer’s proto-
col. Each transfection reaction also contained 2 g of the SEAP
reporter plasmid pG5SEAP. The transfected cells were cultured at
37°C in a 5% CO2 incubator in DMEM (Mediatech) supplemented
with penicillin (100 units/ml), streptomycin (100 g/ml), L-glutamine
(290 g/ml) and heat-inactivated FBS (Hyclone). After 72 hr, super-
natant from the culture was removed and assayed for SEAP activ-
ity. Briefly, 250 µl of the supernatant was heated to 65°C to inacti-
vate any endogenous phosphates, after which it was added to an
equal volume of 2× SEAP buffer (1 mM MgCl2, 20 mM L-homoargi-
nine, and 2 M diethanolamine [pH 9.8]) and incubated at 37°C for
10 min. Finally, 20 µl of 20 mM p-nitrophenol phosphate in 1× SEAP
buffer was added and the OD405 was measured at 5 min intervals
for 1.5 hr using a plate reader (Molecular Devices). The activity was
calculated as the change in light absorbance per minute per sam-
ple. The fold activity of Gal4(1-147)+28 and of the positive control
were derived by comparison to activity obtained for Gal4(1-147).
Each value represents the average of three individual experiments
and the error is reported as the standard deviation of the mean.
Immunofluorescence Staining
To verify that the Gal4(1-147) peptide ligand fusions were being
expressed and transfected in approximately equal amounts in
HEK293 cells, immunofluorescence staining was performed.
Briefly, the transiently transfected cells were fixed on glass slides
using 2% paraformaldehyde. After multiple washes using blocking
buffer (0.05% saponin, 5% BSA, and PBS [pH 7.2]) anti-Gal4 anti-
body (Covance) was added (1:2000 dilution) and incubated for 2 hr
at room temperature. After six 5 min washes, an FITC-conjugated
anti-rabbit secondary antibody (Santa Cruz Biotech) was added
(1:150 dilution) and incubated for 45 min at room temperature. The
slides were then washed with blocking buffer 6 times for 5 min
each and Hoechst (Chemicon), a nuclear stain that enables visual-
ization of all cells, was added to the slides. The cells were visual-
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320ized under a microscope (Leica DM LB connected to Spot RT slider 1
camera, Diagnostic Instruments). The Supplemental Data (Figure
S2) shows images of cells transfected with Gal4(1-147), Gal4 1
(1-147)+28, or Gal4(1-147)+VP16(411-455). The green signal in the
images is due to FITC, indicating the cells that express Gal4, while
1the blue signal is due to the Hoechst stain, showing all the cells.
An overlay of both these images shows that >95% of the cells ex-
pressed the Gal4 fusion proteins.
1
Supplemental Data
1Supplemental Data for this article is available online at http://
www.chembiol.com/cgi/content/full/12/3/313/DC1/.
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